Dublin, June 24, 2019 (GLOBE NEWSWIRE) -- The "Global Tumor Lysis Syndrome (TLS) Market 2018" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed drugs, clinical trials, patent information, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The author estimates that in 2016, there were approximately 12,300 incident cases of tumor lysis syndrome (TLS) worldwide among individuals with high-risk malignancies (acute myeloid leukemia, acute lymphocytic leukemia, and Burkitt's lymphoma).
• The number of incident cases is forecasted to increase to 13,400 by 2025. The marketed drugs for TLS comprise the xanthine oxidase inhibitors Aloprim (allopurinol) and Uloric (febuxostat), and a recombinant urate-oxidase enzyme, Elitek (rasburicase). These therapies are administered via the intravenous and oral routes.
• The overall likelihood of approval of a Phase I hematologic asset is 10.9%, and the average probability a drug advances from Phase III is 57.6%. Drugs, on average, take 8.7 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
• The distribution of clinical trials across Phase I-IV indicates that the majority of trials for TLS have been in the late phases of development, with around 60% in Phase III-IV, and 40% in Phase I-II.
• The US has a substantial lead in the number of TLS clinical trials globally. Clinical trial activity in the TLS space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for TLS, with six in total.
• Sanofi has carried out the most clinical trials in the TLS space, with Menarini being the only other trial sponsor.

Topics Covered

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
Prophylaxis and monitoring
Volume expansion
Medical therapies
Renal replacement therapy

EPIDEMIOLOGY
Incidence assumptions

MARKETED DRUGS
Approvals by country

PROBABILITY OF SUCCESS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase

BIBLIOGRAPHY
Prescription information

APPENDIX

LIST OF FIGURES
Figure 1: Trends in incident cases of TLS in selected high-risk malignancies, 2017-26
Figure 2: Probability of success in the TLS pipeline
Figure 3: Clinical trials in TLS
Figure 4: Top 10 drugs for clinical trials in TLS
Figure 5: Top 10 companies for clinical trials in TLS
Figure 6: Trial locations in TLS
Figure 7: TLS trials status
Figure 8: TLS trials sponsors, by phase

LIST OF TABLES
Table 1: Incident cases of TLS in selected high-risk malignancies, 2017-26
Table 2: Incidence of acute myeloid leukemia, and proportion of individuals with TLS, 2017
Table 3: Incident cases of TLS in acute myeloid leukemia, 2017-26
Table 4: Incidence of acute lymphocytic leukemia, and proportion of individuals with TLS, 2017
Table 5: Incident cases of TLS in acute lymphocytic leukemia, 2017-26
Table 6: Incidence of Burkitt's lymphoma, and proportion of individuals with TLS, 2017
Table 7: Incident cases of TLS in Burkitt's lymphoma, 2017-26
Table 8: Marketed drugs for TLS
Table 9: Approvals by country for TLS
Table 10: Parent patents in TLS
Table 11: Historical global sales, by drug ($m), 2013-17
Table 12: Forecasted global sales, by drug ($m), 2018-22

For more information about this report visit https://www.researchandmarkets.com/r/v216ya

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.